Binod Dhakal, MD
Enriched profileAssociate Professor of Medicine, Division of Hematology and Oncology · Medical College of Wisconsin
Binod Dhakal is Associate Professor of Medicine, Division of Hematology and Oncology at Medical College of Wisconsin. OpenAlex indexes 483 publications with 5,768 citations (h-index 35); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Binod Dhakal, MD, is Associate Professor of Medicine, Division of Hematology and Oncology at Medical College of Wisconsin. The public record shows 483 publications with 5,768 citations (h-index 35), centered on Multiple Myeloma. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 27 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Multiple Myeloma
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 60 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Sponsor: Medical College of Wisconsin
- Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Sponsor: Medical College of Wisconsin
Industry payments
Updated 27 Aug 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202514 payments$25,354openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year202515 payments$19,994openpaymentsdata.cms.gov ↗
- Karyopharm Therapeutics Inc.Program year20259 payments$14,642openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
31.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor31.3%Acyclovir100%Part D≥20 patientsAnti-infectives
22.6%Short-acting sulfonamides9.7%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsFluoroquinolone Antibacterial7.8%Levofloxacin100%Part D≥15 patientsSensory organs
16.1%Corticosteroid16.1%Dexamethasone100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
American journal of hematology
Article2026 - Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.
British journal of haematology
Article2026 - Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Blood cancer journal
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Binod-Dhakal
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →froedtert.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →froedtert.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mcw.edu ↗
Editorial & leadership roles
journal and society appointments- Lead/Principal Investigator
CARTITUDE-4 trial (ciltacabtagene autoleucel, cilta-cel) for relapsed/refractory multiple myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - Core member
Blood & Marrow Transplant Clinical Trials Network (BMT CTN); co-leads national trials on CAR-T and bispecific antibody combinations for high-risk myeloma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fcd.mcw.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fcd.mcw.edu ↗
Awards & honors
honors on the public recordMedia & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- VJHemOnc video interviews on emerging multiple myeloma therapies
CAR-T programs, and next-generation CAR constructs
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Razelle Kurzrock, MD
Medical College of Wisconsin
Mary Horowitz, MD
Medical College of Wisconsin
Janet Rader, MD
Medical College of Wisconsin
Bruce Camitta, MD
Medical College of Wisconsin